Cargando…

Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle

Background. Compared to conventional therapies, biologics are more effective but expensive in treating psoriasis. Objective. To evaluate the efficacy and cost-efficacy of biologic therapies for psoriasis. Methods. We conducted a meta-analysis to calculate the efficacy of etanercept, adalimumab, infl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Ching-Chi, Wang, Shu-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925556/ https://www.ncbi.nlm.nih.gov/pubmed/24605338 http://dx.doi.org/10.1155/2014/862851

Ejemplares similares

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis
por: Geng, Wenjun, et al.
Publicado: (2018)

Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis
por: Golhen, Klervi, et al.
Publicado: (2022)

Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
por: Armstrong, April W., et al.
Publicado: (2021)

Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
por: Lin, Pei-Tzu, et al.
Publicado: (2018)

Meta-Analysis of the Efficacy and Safety of Interleukin-23-Targeted Drugs in the Treatment of Moderate-to-Severe Psoriasis
por: Zhu, Teng, et al.
Publicado: (2022)

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan
por: Chen, Yu-Chen, et al.
Publicado: (2020)

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
por: Armstrong, April, et al.
Publicado: (2022)

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2009)

Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2021)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
por: Leonardi, Craig L., et al.
Publicado: (2022)

Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis
por: Sun, Helen Y., et al.
Publicado: (2021)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials
por: Yang, Jing, et al.
Publicado: (2020)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
por: Hendrix, Nathaniel, et al.
Publicado: (2018)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2015)

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
por: Seyger, M.M.B., et al.
Publicado: (2021)

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
por: Crowley, Jeffrey J., et al.
Publicado: (2022)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

Fitness Use Innovativeness, Usage Patterns and Revisit Intention: The Moderating Role of Other-Efficacy
por: Satjawathee, Theeralak, et al.
Publicado: (2023)

The cost of biologics for psoriasis is increasing
por: Cheng, Judy, et al.
Publicado: (2014)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]
Publicado: (2015)

Efficacy and Safety of Topiramate for Essential Tremor: A Meta-Analysis of Randomized Controlled Trials
por: Chang, Kuo-Hsuan, et al.
Publicado: (2015)

Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response
por: Sawyer, L.M., et al.
Publicado: (2018)

The efficacy of metformin for the treatment of psoriasis: a meta-analysis study
por: Huang, Zhuo, et al.
Publicado: (2023)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)

Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Vickers, Adrian D., et al.
Publicado: (2016)

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
por: Zargaran, Marzieh, et al.
Publicado: (2021)

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021)

Analysis of the Cost and Efficacy of Intra-Articular Knee Injections
por: Pirkle, Sean, et al.
Publicado: (2022)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
por: Körber, Andreas, et al.
Publicado: (2018)

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
por: Adsit, Sandra, et al.
Publicado: (2017)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
por: Talamonti, Marina, et al.
Publicado: (2023)

Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis
por: Tsai, Ya-Chu, et al.
Publicado: (2023)

Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials
por: West, Jonathan, et al.
Publicado: (2016)

Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis
por: Zhou, Hang, et al.
Publicado: (2020)

Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies
por: Liu, Yashu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_38fd0vmev47rie6kdaf8c9nn18